Investigational Drug Information for Imeglimin
✉ Email this page to a colleague
▶ Start for $100
Remove trial restrictions
What is the drug development status for Imeglimin?
Imeglimin is an investigational drug.
There have been 7 clinical trials for Imeglimin.
The most recent clinical trial was a Phase 2 trial, which was initiated on June 1st 2022.
The most common disease conditions in clinical trials are Diabetes Mellitus, Type 2, Diabetes Mellitus, and Liver Diseases. The leading clinical trial sponsors are Poxel SA, Sumitomo Pharma Co., Ltd., and National Center for Global Health and Medicine, Japan.
There are thirty-one US patents protecting this investigational drug and three hundred and fifty-nine international patents.
Summary for Imeglimin
| US Patents | 31 |
| International Patents | 359 |
| US Patent Applications | 75 |
| WIPO Patent Applications | 51 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 2 (2022-06-01) |
| Vendors | 27 |
Recent Clinical Trials for Imeglimin
| Title | Sponsor | Phase |
|---|---|---|
| Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus | Sumitomo Pharma Co., Ltd. | Phase 4 |
| Durable Effect of Imeglimin on the Glycemic Control in Patients With Type 2 Diabetes Mellitus | National Center for Global Health and Medicine, Japan | Phase 4 |
| Pharmacokinetics of Imeglimin in Hepatic Impaired Subjects | Poxel SA | Phase 1 |
Clinical Trial Summary for Imeglimin
Top disease conditions for Imeglimin
Top clinical trial sponsors for Imeglimin
US Patents for Imeglimin
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Imeglimin | ⤷ Sign Up | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | ⤷ Sign Up |
| Imeglimin | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Imeglimin | ⤷ Sign Up | Biguanide compositions and methods of treating metabolic disorders | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | ⤷ Sign Up |
| Imeglimin | ⤷ Sign Up | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk | ELCELYX THERAPEUTICS, INC. (San Diego, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Imeglimin
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Imeglimin | Argentina | AR091089 | 2031-01-07 | ⤷ Sign Up |
| Imeglimin | Argentina | AR091739 | 2031-01-07 | ⤷ Sign Up |
| Imeglimin | Australia | AU2011317140 | 2030-10-19 | ⤷ Sign Up |
| Imeglimin | Australia | AU2011317143 | 2030-10-19 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
